Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 249Breast Neoplasms 197Glioblastoma 196Lung Neoplasms 194Head and Neck Neoplasms 176Squamous Cell Carcinoma of Head and Neck 166Prostatic Neoplasms 164Lymphoma 152Rectal Neoplasms 131Central Nervous System Neoplasms 119Esophageal Neoplasms 117Leukemia 111Brain Neoplasms 99Pancreatic Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 86Esophageal Squamous Cell Carcinoma 83Lymphoma, Follicular 81Sarcoma 80Lymphoma, Large B-Cell, Diffuse 80Uterine Cervical Neoplasms 76Lymphoma, Non-Hodgkin 75Hodgkin Disease 73Neoplasms 68Burkitt Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Colorectal Neoplasms 63Glioma 61Astrocytoma 60Lymphoma, Large-Cell, Immunoblastic 58

Interventions

Radiotherapy 4Immune Checkpoint Inhibitors 4famitinib 1camrelizumab 1aflutinib 1Oxaliplatin 1Nivolumab 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Advanced NSCLC × Radiotherapy × Clear all
NCT06751849 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06751901 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

The First Affiliated Hospital of Nanchang University

Phase 2 Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡